• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Intertek banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Lightlake provides additional details on studies of nasal spray for eating disorders

Lightlake Therapeutics has provided additional details of recently announced Phase 2 trials of its naloxone nasal spray for binge eating disorder and for bulimia nervosa.

Binge eating disorder trials have begun in Helsinki, with 138 patients randomly selected from more than 900 applicants taking either intranasal naloxone or a placebo nasal spray, says the company. Finnish research organization Crown CRO is providing validation, and the trial coordinator is Hannu Eero Rafael Alho, Professor of Addiction Medicine at the University of Helsinki. Lightlake says that it has agreements with Lloyds Pharmacy and Celesio regarding the nasal spray.

The company says that it still plans to begin Phase 2 trials for bulimia nervosa in 2012, with Professor Janet Treasure, head of the Eating Disorders Unit at the South London and Maudsley NHS Trust, and Professor Ulrike Schmidt, a consultant psychiatrist for the Eating Disorders Service and a fellow of the Academy for Eating Disorders as “prospective guides for these trials.”

Lightlake also provided additional information about its expectations for the trial outcomes. Among other things, the new press release asserts that the company “expects the nasal spray is unlikely to be used in a truly chronic manner—patients would only administer the treatment when they have the urge to binge eat, and would require less of the spray over time as they regain control of their eating habits.” The binge eating trial is also evaluating the nasal spray’s ability to reinforce an exercise program and its effects in patients with the A118G genotype.

Read the Lightlake press release.

Share

published on November 2, 2011

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Solstice Air banner
    © 2025 OINDPnews